Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)
for Migraine
Drug: Ubrogepant
109 locations incl. Huntsville
Sponsor: AbbVie
Sex: All·Age: 6 - 17
Code: NCT05127954·Phase 3·Enrolling By Invitation